This Apoptopic Drugs in Oncology Report Focuses Specifically on Breast and Prostate Cancer
Posted on: Tuesday, 25 March 2008, 09:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c86619) has announced the addition of "Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer" to their offering.
This is the report for professionals interested to grasp the field of apoptopic drug targets in oncology and at the same time have an extensive R&D overview of breast- and prostate cancer. This extensive 450+ pages report compiles and analyzes Apoptosis, the type of death about whose genetically controlled pathways we know the most, and further gives an in depth analysis in two key oncology areas; Breast- and Prostate cancer
In the report, the author reports on 90 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 114 apoptopic drugs designed for the treatment of 48 different cancer indications.
To fuel the scientific and competitive thinking, the author opens the gate into the presence and relevance of protein-protein interactions between identified targets of apoptopic drugs. No less than 452 protein-protein interactions were recognized among 96 of the 119 included apoptopic drug targets.
This report section by the numbers
A hundred different tables. Includes more than 1,500 active links to related resources on the Internet
114 apoptopic drugs, under development by 87 investigators, are included, covering more than 430 developmental projects in cancer
119 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other apoptopic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
90 Unique drug target combinations of apoptopic drugs
452 protein-protein interactions among apoptopic drug targets
Extensive pathway analysis of drug targets
Contents:
1 Executive Summary
2 Methodologies
3 Table of Contents
4 Introduction to Apoptotic Drugs in Oncology
5 Apoptopic Drug Compound Types and Sub-cellular Localizations of Targets
6 The Cancer Genome Project and Apoptopic Drug Targets
7 Protein Expression Profiles of Apoptopic Drug Targets in Human
8 Pathway Analysis of Drug Targets of Apoptopic Drugs
9 Protein-Protein Interactions Between Identified Apoptopic Drug Targets
10 Available Biological Structure Data on Apoptopic Drug Targets
11 Drug Target Profiles of Apoptopic Drug Targets in Oncology
12 Apoptopic Drug Target Mix by Development Stage
13 Apoptopic Drug Target Mix by Cancer Indication
14 Apoptopic Drugs and their Targets by Companies
15 Breast Cancer: An Introduction
16 Current Treatment Strategies of Breast cancer
17 Progress in Current Breast Cancer Treatment Strategies
18 Key Therapeutic Strategies for Future Breast Cancer Therapies
19 Competitive Landscape in Breast Cancer Drug Development: The Late Stage Pipeline
20 Current Drug Development for Breast Cancer: The Early Stage Pipeline 20.1 DNA Targeting
21 Prostate Cancer: An Introduction
22 Current Prostate Cancer Treatment Strategies
23 Progress in Current Prostate Cancer Treatment Strategies
24 Key Therapeutic Strategies for Future Prostate Cancer Therapies
25 Competitive Landscape in Prostate Cancer Drug Development: The Late Stage Pipeline
26 Current Prostate Cancer Drug Development: The Early Stage Pipeline
27 Disclaimer
28 Drug Index
29 Company Index
List of Tables
31 List of Boxes
32 List of Figures
Figure 1: Distribution of Compound Types Among Apoptopic Drugs
Figure 2: Primary Sub-cellular Localization of Drug Targets
For more information visit http://www.researchandmarkets.com/reports/c86619
Source: Business Wire
Related Articles
- Examine Injectable Drug Delivery Technologies, Targets and Therapeutics With This Essential and Comprehensive Report
- Current Pharmaceutical Pipelines Are Testimony to the Intensity of Breast Cancer Drug Development With At Least 50 Investigational Drugs/Drug Combinations in Clinical Development
- Immunomedics Develops Two New Drug Immunoconjugates For Targeted Therapy of Colon and Lung Cancers
- Drug "halves breast cancer relapse rate"
- Drug halves breast cancer relapse rate for some
- Kinex Pharmaceuticals Selects Lead Drug Candidate for Clinical Development in Oncology
- Activated Stat5 Protein in Prostate Cancer Can Predict Outcome
- Peptides and Therapeutic Proteins: New Opportunities for Macromolecule Development, Delivery, and Commercialization
- Moffitt-USF Head Toward First Human Trials of Anti-cancer Drug that Targets Protein AKT
- MicroRNA Tweaks Protein that Controls Early Heart Development
User Comments (0)

RSS Feeds